Aileron Therapeutics, Inc. (ALRN)
Largest Insider Buys in Sector
ALRN Stock Price History Chart
ALRN Stock Performance
About Aileron Therapeutics, Inc.
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in …
Insider Activity of Aileron Therapeutics, Inc.
Over the last 12 months, insiders at Aileron Therapeutics, Inc. have bought $898 and sold $281,909 worth of Aileron Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aileron Therapeutics, Inc. have bought $3.56M and sold $281,909 worth of stock each year.
Highest buying activity among insiders over the last 12 months: WINDSOR JAMES BRIAN (President and CEO) — $898.
The last purchase of 400 shares for transaction amount of $898 was made by WINDSOR JAMES BRIAN (President and CEO) on 2024‑12‑05.
List of Insider Buy and Sell Transactions, Aileron Therapeutics, Inc.
| 2024-12-05 | President and CEO | 400 0.0018% | $2.24 | $898 | -8.62% | |||
| 2024-06-17 | Sale | 10 percent owner | 4,707 0.0219% | $3.25 | $15,298 | -13.08% | ||
| 2024-06-14 | Sale | 10 percent owner | 1,900 0.009% | $3.30 | $6,270 | -13.20% | ||
| 2024-06-12 | Sale | 10 percent owner | 9,342 0.0435% | $3.25 | $30,362 | -13.85% | ||
| 2024-06-11 | Sale | 10 percent owner | 5,752 0.0269% | $3.26 | $18,744 | -13.31% | ||
| 2024-06-10 | Sale | 10 percent owner | 9,577 0.046% | $3.30 | $31,604 | -11.16% | ||
| 2024-06-07 | Sale | 10 percent owner | 1,740 0.0081% | $3.26 | $5,664 | -12.04% | ||
| 2024-06-06 | Sale | 10 percent owner | 4,284 0.0199% | $3.29 | $14,104 | -13.22% | ||
| 2024-06-05 | Sale | 10 percent owner | 6,291 0.0291% | $3.30 | $20,760 | -13.33% | ||
| 2024-05-01 | Sale | 10 percent owner | 20,315 0.1211% | $4.21 | $85,473 | -25.00% | ||
| 2024-04-30 | Sale | 10 percent owner | 90 0.0006% | $4.97 | $448 | -31.32% | ||
| 2024-04-29 | Sale | 10 percent owner | 10,746 0.0637% | $4.95 | $53,182 | -36.38% | ||
| 2023-12-15 | President and COO | 225 0.0043% | $3.37 | $758 | +2.80% | |||
| 2023-11-20 | President and COO | 5,076 0.1087% | $1.97 | $9,987 | +92.04% | |||
| 2021-01-08 | See Remarks | 9M 8.7946% | $1.10 | $9.9M | -14.81% | |||
| 2020-06-15 | director | 5,800 0.0189% | $1.22 | $7,076 | +2.50% | |||
| 2020-06-08 | 3.7M 11.0475% | $1.10 | $4.07M | +4.24% | ||||
| 2020-06-08 | director | 227,272 0.6786% | $1.10 | $249,999 | +4.24% | |||
| 2019-11-15 | director | 39,142 0.1624% | $0.51 | $19,962 | +60.68% | |||
| 2019-11-14 | director | 15,858 0.0646% | $0.51 | $8,088 | +57.84% |
Insider Historical Profitability
| WINDSOR JAMES BRIAN | President and CEO | 239 0.0011% | $1.75 | 3 | 0 | |
| Satter Muneer A | See Remarks | 16609449 76.6617% | $1.75 | 3 | 0 | <0.0001% |
| Novartis Bioventures Ltd | 10 percent owner | 2079394 9.5975% | $1.75 | 1 | 27 | <0.0001% |
| Gallagher Brian M. Jr. | director | 1431519 6.6072% | $1.75 | 1 | 0 | <0.0001% |
| Shanafelt Armen | director | 1094987 5.054% | $1.75 | 1 | 0 | <0.0001% |